"Expanding knowledge and access
to emergency contraception"
"Expanding knowledge and access to emergency contraception in Europe"
These posts appear under the ‘Featured’ heading.
Help us learn more about how real access to emergency contraception (EC) is in Europe! July / Sept 2019. The European Youth Network on Sexual and Reproductive Rights (YouAct) and ECEC, launch the first participatory survey on pharmacy access to EC in Europe. With this effort, we want to: Learn how EC products are placed and stocked in…
January 2019. The International Federation of Gynecology and Obstetrics (FIGO) and the International Consortium for Emergency Contraception (ICEC), launch the 4th edition of “Emergency Contraceptive Pills: Medical and Service Delivery Guidance”. The guidance is designed to serve as a key reference and training document for service provision. It includes a range of medical and service delivery…
December 2018. The World Health Organization (WHO) recently launched two new Apps for healthcare providers advising women on contraception. The “Humanitarian settings contraception” App, is intended for front-line health care providers to help women initiate contraception in humanitarian and emergency settings. More information here. The “WHO MEC” App, will facilitate the task of family planning…
“Emergency contraception methods” (the EC wheel), a counselling tool for pharmacists and health providers published in May 2016 by ECEC, is now available in French, and can be used from tablets, cellphones and computers (on and off line). This tool is inspired in the WHO Medical eligibility criteria for contraceptive use (MEC) wheel, and based on the…
Over the past year, there have been discussions around whether hormonal contraception should be resumed immediately after the intake of UPA EC. The concern is that using a progestin-containing contraceptive could counteract the effects of UPA EC. UPA is an anti-progestin that works by delaying or inhibiting ovulation; if a progestin-containing contraceptive is administered at the…
HRA Pharma announced that the European Commission, in a historic ruling, has authorized the emergency contraceptive ellaOne® to be accessible directly from pharmacies without the need for a prescription from a doctor. This is the first ever decision of its type regarding any oral contraceptive product applicable to all EU member states, according to national…
On November 21st 2014, the European Medicines Agency (EMA) recommended that the EC pill containing ulipristal acetate, be made available without the need for a prescription in all European Union countries. EMA recommendation should be implemented in a few months, once it has been endorsed by the European Commission. For further information, please read EM’As…
The European Medicines Agency (EMA) released the following statement today: “The European Medicines Agency has concluded its review of emergency contraceptives containing levonorgestrel or ulipristal acetate to assess whether increased bodyweight affects the effectiveness of these medicines in preventing unintended pregnancy following unprotected sexual intercourse or contraceptive failure. The Agency’s Committee for Medicinal Products for Human…
Beginning in January 2014, the European Medicines Agency (EMA) started reviewing emergency contraceptives to assess whether increased body weight and body mass index (BMI) reduce the efficacy of these medications. Based on the results of this review, EMA will assess whether any changes should be made to the product information for emergency contraceptives containing levonorgestrel…
ECEC has published an article in WHO’s Entre Nous European Magazine for Sexual and Reproductive Health. In it, ECEC outlines the unequal EC access situation in Europe and advocates for the standardization of EC guidelines across the continent to help reduce these inequalities. Ultimately, ECEC recommends that every woman seeking EC be informed of the…
Do you want to know more about access to emergency contraception in a specific country? In cooperation with national experts, ECEC is developing country profiles. Click here to learn more about EC accessibility, prescription status, cost, guidelines, common practices, and use in European countries.
The Center for Reproductive Rights recently released a fact sheet titled “Access to Contraceptives in the European Union: Human Rights, Barriers and Good Practices,” which outlines different barriers to access in the region and highlights some examples considered best practices. Although states are obligated under international law to provide women with access to a full…
Menú
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!
More information about our Cookie Policy
